308 related articles for article (PubMed ID: 37866632)
1. Redirecting the specificity of tripartite motif containing-21 scaffolds using a novel discovery and design approach.
VanDyke D; Xu L; Sargunas PR; Gilbreth RN; Baca M; Gao C; Hunt J; Spangler JB
J Biol Chem; 2023 Dec; 299(12):105381. PubMed ID: 37866632
[TBL] [Abstract][Full Text] [Related]
2. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
3. Homo-PROTACs: bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation.
Maniaci C; Hughes SJ; Testa A; Chen W; Lamont DJ; Rocha S; Alessi DR; Romeo R; Ciulli A
Nat Commun; 2017 Oct; 8(1):830. PubMed ID: 29018234
[TBL] [Abstract][Full Text] [Related]
4. bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA).
Lim S; Khoo R; Peh KM; Teo J; Chang SC; Ng S; Beilhartz GL; Melnyk RA; Johannes CW; Brown CJ; Lane DP; Henry B; Partridge AW
Proc Natl Acad Sci U S A; 2020 Mar; 117(11):5791-5800. PubMed ID: 32123106
[TBL] [Abstract][Full Text] [Related]
5. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
Reboud-Ravaux M
Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
[TBL] [Abstract][Full Text] [Related]
6. Ligandability of E3 Ligases for Targeted Protein Degradation Applications.
Belcher BP; Ward CC; Nomura DK
Biochemistry; 2023 Feb; 62(3):588-600. PubMed ID: 34473924
[TBL] [Abstract][Full Text] [Related]
7. The E3 Ubiquitin Ligase TRIM21 Promotes HBV DNA Polymerase Degradation.
Mu T; Zhao X; Zhu Y; Fan H; Tang H
Viruses; 2020 Mar; 12(3):. PubMed ID: 32245233
[TBL] [Abstract][Full Text] [Related]
8. TRIM21-dependent target protein ubiquitination mediates cell-free Trim-Away.
Mevissen TET; Prasad AV; Walter JC
Cell Rep; 2023 Feb; 42(2):112125. PubMed ID: 36807144
[TBL] [Abstract][Full Text] [Related]
9. Covalent fragment-based ligand screening approaches for identification of novel ubiquitin proteasome system modulators.
Rothweiler EM; Brennan PE; Huber KVM
Biol Chem; 2022 Mar; 403(4):391-402. PubMed ID: 35191283
[TBL] [Abstract][Full Text] [Related]
10. Association of connexin43 with E3 ubiquitin ligase TRIM21 reveals a mechanism for gap junction phosphodegron control.
Chen VC; Kristensen AR; Foster LJ; Naus CC
J Proteome Res; 2012 Dec; 11(12):6134-46. PubMed ID: 23106098
[TBL] [Abstract][Full Text] [Related]
11. Targeted protein degradation via intramolecular bivalent glues.
Hsia O; Hinterndorfer M; Cowan AD; Iso K; Ishida T; Sundaramoorthy R; Nakasone MA; Imrichova H; Schätz C; Rukavina A; Husnjak K; Wegner M; Correa-Sáez A; Craigon C; Casement R; Maniaci C; Testa A; Kaulich M; Dikic I; Winter GE; Ciulli A
Nature; 2024 Mar; 627(8002):204-211. PubMed ID: 38383787
[TBL] [Abstract][Full Text] [Related]
12. Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation.
Xi M; Chen Y; Yang H; Xu H; Du K; Wu C; Xu Y; Deng L; Luo X; Yu L; Wu Y; Gao X; Cai T; Chen B; Shen R; Sun H
Eur J Med Chem; 2019 Jul; 174():159-180. PubMed ID: 31035238
[TBL] [Abstract][Full Text] [Related]
13. Receptor Elimination by E3 Ubiquitin Ligase Recruitment (REULR): A Targeted Protein Degradation Toolbox.
Siepe DH; Picton LK; Garcia KC
ACS Synth Biol; 2023 Apr; 12(4):1081-1093. PubMed ID: 37011906
[TBL] [Abstract][Full Text] [Related]
14. Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory.
Cowan AD; Ciulli A
Annu Rev Biochem; 2022 Jun; 91():295-319. PubMed ID: 35320687
[TBL] [Abstract][Full Text] [Related]
15. Proteasome substrate receptors and their therapeutic potential.
Osei-Amponsa V; Walters KJ
Trends Biochem Sci; 2022 Nov; 47(11):950-964. PubMed ID: 35817651
[TBL] [Abstract][Full Text] [Related]
16. Crbn-based molecular Glues: Breakthroughs and perspectives.
An J; Zhang X
Bioorg Med Chem; 2024 Apr; 104():117683. PubMed ID: 38552596
[TBL] [Abstract][Full Text] [Related]
17. Proteolysis-targeting chimeras (PROTACs) in cancer therapy.
Li X; Pu W; Zheng Q; Ai M; Chen S; Peng Y
Mol Cancer; 2022 Apr; 21(1):99. PubMed ID: 35410300
[TBL] [Abstract][Full Text] [Related]
18. Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets.
Moon S; Lee BH
Mol Cells; 2018 Nov; 41(11):933-942. PubMed ID: 30486612
[TBL] [Abstract][Full Text] [Related]
19. Mathematical Model for Covalent Proteolysis Targeting Chimeras: Thermodynamics and Kinetics Underlying Catalytic Efficiency.
Chaudhry C
J Med Chem; 2023 May; 66(9):6239-6250. PubMed ID: 37102218
[TBL] [Abstract][Full Text] [Related]
20. Design Principles Involving Protein Disorder Facilitate Specific Substrate Selection and Degradation by the Ubiquitin-Proteasome System.
Guharoy M; Bhowmick P; Tompa P
J Biol Chem; 2016 Mar; 291(13):6723-31. PubMed ID: 26851277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
